#United States #Portland #Neurotherapeutics #MedRhythms #Larry Jasinski

MedRhythms Appoints New Leadership

In a pivotal move for MedRhythms, Inc., renowned for pioneering next-generation neurotherapeutics, the company has announced the appointment of Larry Jasinski as its new Chief Executive Officer (CEO). This strategic decision, effective immediately, marks the beginning of a new chapter intended to drive the company's growth and commercial expansion.

MedRhythms is widely recognized for developing a revolutionary prescription music platform aimed at improving mobility and walking capabilities through innovative neurotherapeutic solutions. As the company prepares to expand its market share, the board of directors has expressed confidence in Jasinski's ability to lead these initiatives given his extensive background in the medical device and neurotechnology sectors.

Larry Jasinski comes to MedRhythms with over 30 years of leadership experience. His previous role as CEO at Lifeward (formerly ReWalk Robotics) was marked by significant successes, including a successful IPO and establishing national reimbursement for pioneering spinal cord injury technologies. Prior to his tenure at Lifeward, he served as President and CEO at Soteira, Inc., which was later acquired by Globus Medical.

The board's decision to select Jasinski was unanimous, and they are eager to see how his leadership will enhance the product's market adoption and drive the company into its next growth phase. Jean Hoffman, a board member and chair of the CEO search committee, stated, "The Board and major investors are excited to welcome Larry to the team and eagerly look forward to his leadership in ushering us into this next phase."

In response to his appointment, Jasinski shared his thoughts: "MedRhythms possesses groundbreaking technology, robust clinical data, and a compelling product that is both effective and user-friendly. This is a sizable market opportunity with substantial growth potential and I’m honored to be part of a mission-driven team dedicated to improving lives through the company's innovative therapeutic approaches."

The transition of co-founder Brian Harris to Chief Scientific Officer (CSO) also highlights the strategic planning at MedRhythms. Harris was instrumental in navigating the company through significant milestones such as clinical trials, FDA product listings, and securing benefits categories from the Centers for Medicare and Medicaid Services (CMS). His experience will be invaluable as he collaborates with Jasinski to further the company's mission.

The appointment of Jasinski comes at a crucial moment as MedRhythms prepares to roll out its home-use products designed for various walking impairments, including the InTandem® platform for chronic stroke patients and Movive™, targeted at individuals with Parkinson's disease. Both products have received FDA Class II device listings and are being positioned for distribution across federal healthcare systems.

MedRhythms is leveraging its proprietary technology, which integrates sensors, software, and music underpinned by advanced neuroscience, to create a pipeline of products addressing various neurological conditions. This includes strokes and multiple sclerosis, marking a substantial evolution in neurorehabilitation.

In a bid to enhance its growth trajectory and market impact, MedRhythms recently secured a partnership with Universal Music Group and completed a successful Series B financing round led by Morningside Ventures and Advantage Capital. With headquarters in Portland, Maine, the firm is poised for nationwide expansion.

As MedRhythms steps into this new era of leadership with Larry Jasinski at the helm, the company looks forward to scaling its innovative solutions to help enhance the quality of life for those with chronic health conditions and mobility challenges. For more information about MedRhythms and their efforts in neurotherapeutics, visit www.medrhythms.com.